Aptose TUSCANY abstract accepted for ASH 2025 poster session

Aptose Biosciences Inc.

Abstract #1645 from TUSCANY trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML selected for ASH 2025 poster presentation.
Poster session December 6, 2025, 5:30-7:30 PM in Orlando, FL.
Abstract available now; additional data to be presented in the poster.
Aptose developing tuspetinib-based triple therapy for patients ineligible for induction chemo.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.